








Disease Monograph Series – 15 








Bovine Tuberculosis | Monograph 15 













This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre (IDRC) over the period Nov 2015 to April 
2016 to inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The 
LVIF is a seven-and-a-half year, CA$57 million partnership between the Bill & Melinda 
Gates Foundation, Global Affairs Canada and Canada’s International Development 
Research Centre. It focuses on those animal diseases posing the greatest risk to poor 
livestock keepers in Sub-Saharan Africa, South and Southeast Asia, targeting 
transboundary diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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Disease, etiology, epidemiology and impact 
Bovine tuberculosis (bTB) is a chronic bacterial disease of animals and humans caused by Mycobacterium bovis. 
In a large number of countries, it is a major infectious disease of cattle, other domesticated animals, and certain 
wildlife populations.  
Mycobacterium bovis belongs to the Mycobacterium tuberculosis complex (MTBC) that causes tuberculosis in 
humans and animals. The most important members of the MTBC are M. bovis and M. tuberculosis. In certain 
regions, M. caprae is also relevant.  M. tuberculosis is avirulent for cattle, although it is able to cause localized 
lesions. Goats are highly susceptible to M. bovis and M. caprae.  Bovine TB is usually maintained in cattle 
populations, but a few other species can become reservoir hosts. Most species are considered to be spillover 
hosts (do not maintain M. bovis in the absence of maintenance hosts). M. bovis can be transmitted by the 
inhalation of aerosols, by ingestion, or through breaks in the skin.  
Bovine TB generally has a chronic, and often subclinical course.  It usually takes many months or even years 
before clinical signs develop and they depend on the organ or systems involved and the severity of the infection. 
It is usually characterized by formation of nodular granulomas known as tubercles.  
Bovine TB causes significant economic hardship for livestock farmers with estimates of >50 million cattle 
infected worldwide, costing $3 billion annually. It includes costs associated with reduction in productivity in 
severely affected animals, testing, culling of affected animals, indemnity payments, movement controls, 
restrictions on trade, maintenance of control programs, and research to develop improved control strategies 
 
Zoonotic disease 
M. bovis infects humans primarily due to the ingestion of unpasteurized dairy products, and it is more associated 
with extra-pulmonary TB in humans (EPTB). It is rare in humans in developed countries due to the eradication 
and control programs they have put in place. Unfortunately, it is still common in less developed countries.   
TB caused by M. bovis in humans is much less common than TB caused by M. tuberculosis. Due to difficulties in 
diagnostics, is difficult to discern the true global load of human TB caused by M. bovis. There were estimates 
mentioning 3.1% of all TB worldwide to be zoonotic TB, but most recent data mentions 2.8% for Africa. The 
latest data as shown in Table 7 confirms that it is very low, unless for certain specific hotspots. Differentiation of 
TB caused by M. bovis is relevant, as M. bovis is naturally resistant to pyrazinamide, one of the four first-line 
anti-tuberculosis drugs and prognosis is often poor. The WHO estimates the Disability adjusted life years (DALYs) 
due to M. bovis to be 607,775, and 9 DALYs per 100,000 persons (2015 data).   
 
Bovine Tuberculosis | Monograph 15 






Incidence / Prevalence 
Although bovine tuberculosis was once found worldwide, control programs have eliminated or nearly eliminated 
this disease from domesticated animals in many countries. Bovine TB is still widespread in Africa, parts of Asia 
and the Americas, and some Middle Eastern countries. Surprisingly, there is not much recent data on prevalence 
in the focus countries (with some exceptions such as Ethiopia) and there is virtually no information on the 
prevalence of M. bovis in small ruminants. It would seem the disease is more prevalent in peri-urban dairy 
settings, than in rural pastoralist areas.  
 
Diagnostics 
Diagnosis in the live animal is usually based on delayed hypersensitivity reactions (tuberculin skin test). 
Traditional mycobacterial culture remains the gold standard method for routine confirmation of infection. Blood 
tests based on gamma-interferon, lymphocyte proliferation assay and indirect ELISA are also available, but are 
mainly used to confirm a skin test.  
Current tests have many challenges, but there have been recent developments. Most promising is a DIVA skin 
test developed by AgResearch in New Zealand, which will be commercialized soon, but needs to be validated in 
developing countries as the exposure to environmental mycobacteria will be different. There are also improved 
blood tests. Quality and availability of tuberculin is also a challenge.   
 
Control 
Bovine TB is usually a notifiable disease, but not in all focus countries. There are four principal approaches to the 
control of tuberculosis: 1) test and slaughter, 2) test and segregation, 3) Immunization and 4) Chemotherapy. 
Chemotherapy requires a long time, and is forbidden in the majority of the countries.  Immunization has not 
been very effective, and it does not allow the differentiation between vaccinated and infected animals. It is 
forbidden in many countries. The main measures used have been test and slaughter, and test and segregation. 
However, these last 2 measures are very difficult to implement in developing countries.   
Presence of bTB in wildlife, generates additional complications for control. This is a big problem in UK and USA, 
but also presents challenges in Africa, in the livestock-wildlife interface.   
 
Current vaccines 
A commercial vaccine licensed for use in cattle for bTB does not exist. The vaccine for human TB, the BCG (a live 
attenuated M. bovis strain), has been used in cattle, and remains the best candidate vaccine for use in the field 
in the short to medium term. Some advantages include that the vaccine is safe, inexpensive and is commercially 
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produced for human application. The safety of BCG has been demonstrated for multiple host species, including 
cattle in numerous trials over the past 90 years. The major caveats which have restricted its use, is that BCG 
protection is not complete. It limits mycobacterial burden and associated pathology in cattle but does not 
prevent infection. It also sensitises animals to respond in traditional TB tests. Some of these limitations are 
understandable for countries undergoing eradication, but in settings where the disease is a real problem, there 
is not an eradication or control program in place (the DIVA capability is not a major issue) and there is not a 
better option, BCG seems a reasonable alternative.  However, there is not enough experience in using the 
vaccine in those settings, and there are important knowledge gaps in how to best use the vaccine in those 
scenarios, for example efficacy of a smaller dose (which would reduce the cost), and duration of immunity.  Field 
trials for an integrated control of bTB with BCG vaccine should be recommended where the conditions are 
appropriate. This will also provide the opportunity to evaluate BCG effect on disease transmission.  
The highlights of the recent developments on the use of BCG are shown in Table 10.  
 
Research and potential new vaccine candidates 
There is a need for a livestock vaccine that prevents infection and provides sterilizing immunity, that has DIVA 
capabilities and has a longer duration of immunity. Relatively large amounts are being invested by developed 
countries like UK and USA, where bTB control is a challenge, and vaccines for livestock and/or wildlife would be 
of help. However, they are focused on their needs, that might be slightly different from the ones of the 
developing countries.  
Research is being conducted using different approaches:  improvement of the current BCG, strategies to 
improve BCG vaccination by boosting it with different antigens, live attenuated vaccines using mainly M. bovis 
(and in some instances M. tuberculosis), DNA, adjuvanted proteins and virus vector vaccines.  A summary is 
presented in Table 13. Many of the candidates have DIVA capability. So far, the best results in cattle have been 
achieved with strategies using combinations of BCG with subunit vaccines (heterologous prime-boost strategies) 
as shown in Tables 13 and 14. 
Current research projects include several combination vaccines or strategies. For example, work is being done by 
Dr Waters and his team on developing a novel strategy in which an attenuated Mannheimia haemolytica-
vectored subunit vaccine is administered intranasally and simultaneous with parenteral BCG.  Other groups are 
working on combination with Brucellosis (mainly from Argentina and Brazil), and a group has published about a 
combination with bovine viral diarrhea.  
There are potential synergies with human TB vaccines, so developments in that area should be watched 
carefully.  
 
Suggested characteristics of an ideal bTB vaccine, can be seen under the Target Product Profile in Section 9. 
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Bovine tuberculosis (bTB) is a chronic bacterial disease of animals and humans caused by Mycobacterium bovis. 
In a large number of countries, it is a major infectious disease of cattle, other domesticated animals, and certain 
wildlife populations. It is a zoonosis 
 
Etiology & Epidemiology 
 
Bovine TB is caused by Mycobacterium bovis. The genus Mycobacterium consists of about 50 species, most of 
which are environmental saprophytes that exist and multiply in a wide variety of substrates such as soil, water 
and plants, domestic and wild mammals and birds.  Certain members of the genus, such as those that make up 
what is known as the M. tuberculosis complex, are also known as “tubercle bacilli” due to their causing 
tuberculosis in humans and animals. These are obligate parasites and are usually transmitted only by infected 
mammalian hosts.  The mycobacteria of the M. tuberculosis complex are characterized by 99.9% similarity at the 
nucleotide level and identical 16S r RNA, but they differ in phenotypes and host tropism.  
 
Mycobacterium tuberculosis complex (MTBC) 
Host adaption of the MTBC is not strict. All members have been found to cause disease in humans, and many 
have been isolated from mammals that are not considered to be the primary host (see Table 1 and Figure 1).  
This led to the concept of a “maintenance” host, to which each species of the MTBC is adapted, and “spillover” 
hosts, in which the disease can be found but is not necessarily maintained [1]. The most important members of 
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Table 1: Ten leading disease losses globally by livestock disease units (LSU) loss 
 
 Primary Host Other hosts  Comments 
M. tuberculosis Humans Sometimes reported in animals Obligate human pathogen. 
M. africanum Humans Rarely reported in animals Obligate human pathogen. Limited to West 
Africa 
M. canetti Humans  Opportunistic human pathogen. Associated 
to the Horn of Africa. “smooth TB bacilli”. 
M. bovis Cattle Other domestic and wild 
mammals, humans 
 
M. caprae Goats and sheep Cattle, red deer, wild boar and to 
a limited extent, humans.  
Found almost exclusively in continental 
Europe but information from the Middle 
East, Asian, or African countries is missing 
[2] 
M. microti Rodents (voles) Not considered an important 
pathogen for domestic or wild 
animals 
 
M. pinnipedii Seals and sea lions   
M. mungi Banded 
mongooses 
Unknown Isolated in Botswana from mongooses 
living near humans in Chobe District, 
Botswana 
M. orygis Not known Not clear but includes: Oryxes, 
waterbucks, gazelles, cows, 
rhesus monkeys 
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Tuberculosis in livestock 
Mycobacterium bovis, causes tuberculosis in cattle, but may also affect other species, including humans.  M. 
bovis is the most universal pathogen among the mycobacteria, and produces progressive disease in many 
domestic and wild animals, as well as humans.  
Bovine TB is usually maintained in cattle populations, but a few other species can become reservoir hosts. 
Known maintenance hosts include brush–tailed possums (and possibly ferrets) in New Zealand, badgers in the 
United Kingdom and Ireland, bison and elk in Canada, and kudu and African buffalo in southern Africa.  Most 
species are considered to be spillover hosts. Populations of spillover hosts do not maintain M. bovis indefinitely 
in the absence of maintenance hosts, but may transmit the infection between their members (or to other 
species) for a time. Some spillover hosts can become maintenance hosts if their population density is high. 
Species reported to be spillover hosts include sheep, goats, horses, pigs, dogs, cats, ferrets, camels, llamas, many 
species of wild ruminants including deer and elk; elephants, rhinoceroses, foxes, coyotes, mink, primates, 
opossums, otters, seals, sea lions, hares, raccoons, bears, warthogs, large cats (including lions, tigers, leopards, 
cheetahs and lynx) and several species of rodents. Most mammals may be susceptible 
M. tuberculosis was already shown in the 19th century to be avirulent in cattle. Localized lesions might develop, 
but infection does not result in progressive disease. More recently, Whelan et al [4] confirmed it with strain M. 
tuberculosis H37Rv. They proposed that the immune status of the animal, or genotype of the infecting bacillus, 
may have significant bearing on the virulence of a strain for cattle. There is currently no evidence of animal-to-
animal transmission of M. tuberculosis or M. africanum [5] in cattle, but they may cause reactions in tuberculin-
tested cattle. 
Goats are highly susceptible to M. bovis and M. caprae. Caprine TB has been underestimated for a long time, 
although it causes economic losses in endemic areas, and goats in contact with cattle might act as reservoirs of 
bTB [6]. Interestingly, caprine TB is not an OIE noticeable disease.  
 
Transmission 
M. bovis can be transmitted by the inhalation of aerosols, by ingestion, or through breaks in the skin. The 
importance of these routes varies between host species.  
Cattle shed M. bovis in respiratory secretions, feces and milk, and sometimes in the urine, vaginal secretions or 
semen. The risk of infection from infected cattle is dependent on them shedding the organism. Bacteria are shed 
consistently soon after the initial infection; at a later stage shedding becomes intermittent, and large numbers of 
organisms may be shed in the late stages of infection. Asymptomatic and anergic carriers occur. In most cases, 
M. bovis is transmitted between cattle in aerosols during close contact. Some animals become infected when 
they ingest the organism; this route may be particularly important in calves that nurse from infected cows. 
Cutaneous, genital, and congenital infections have been seen but are rare. Not all infected cattle may transmit 
the disease. Humans with open tuberculosis caused by M. bovis can infect cattle by the aerogenous route when 
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handling them or by contaminating the closed environment of a stable by spitting or urinating. The primary 
mode of spread of bTB between herds is by the introduction of infected animals. In certain areas, wild animals 




Figure 1: Updated phylogeny of the Mycobacterium tuberculosis complex. Source: van Ingen et al, 2012 [3] 
 
Ingestion appears to be the primary route of transmission in pigs, ferrets, cats and probably deer. Cats can be 
infected by the respiratory route or via percutaneous transmission in bites and scratches. Nonhuman primates 
are usually infected by inhalation. Aerosol transmission also seems to be the main route of spread in badgers, 
but transmission in bite wounds can be significant. Badgers with advanced disease can shed M. bovis in the 
urine, and organisms have been found in the feces.  
M. bovis can survive for several months in the environment, particularly in cold, dark and moist conditions. At 
12-24°C, the survival time varies from 18 to 332 days, depending on the exposure to sunlight.  
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Bovine TB generally has a chronic, variable, and often subclinical course.  Occasionally it can be acute and rapidly 
progressive. It usually takes many months or even years before clinical signs develop.  In most infected cattle the 
disease is inapparent, and it is only being detectable by the tuberculin test.  If clinical signs are manifested, their 
nature depends on the organ system or systems involved and the severity of the infection. It is usually 
characterized by formation of nodular granulomas known as tubercles. Any body tissue can be affected, but 
lesions are most frequently observed in the lymph nodes (particularly in the head and thorax), lungs, intestines, 
liver, spleen, pleura, and peritoneum.  
In countries where control is active and aggressive, the disease is primarily respiratory in nature and the extent 
of the lesions is limited. In countries where the disease is not actively controlled, advanced disease and 
generalization are common.  
In the late stages of the disease, common symptoms include progressive emaciation, a low–grade fluctuating 
fever, weakness and inappetence. Animals with pulmonary involvement usually have a moist cough that is 
worse in the morning, during cold weather or exercise, and may have dyspnea or tachypnea. In the terminal 
stages, animals may become extremely emaciated and develop acute respiratory distress. In some animals, the 
retropharyngeal or other lymph nodes enlarge and may rupture and drain. Greatly enlarged lymph nodes can 
also obstruct blood vessels, airways, or the digestive tract. If the digestive tract is involved, intermittent diarrhea 
and constipation may be seen. In some animals, the only symptom may be abscesses of unknown origin in 
isolated lymph nodes, and symptoms may not develop for several years. In other cases, the disease may be 




Bovine TB infection in cattle is usually diagnosed in the live animal on the basis of delayed hypersensitivity 
reactions. Traditional mycobacterial culture remains the gold standard method for routine confirmation of 
infection.  
• Post-mortem:  Bovine TB is characterised by the formation of granulomas (or tubercles). They are 
usually yellowish and either caseous, or caseo-calcified. They are often encapsulated.  
• OIE recognized tests: 
a) Identification of the agent: Isolation of mycobacteria on selective culture media, and their 
subsequent identification by cultural and biochemical tests or DNA techniques such as PCR. 
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b) Delayed hypersensitivity test using bovine tuberculin purified protein derivative (PPD), which is 
the prescribed test for international trade. It involves measuring skin thickness, injecting bovine 
tuberculin intradermally into the measured area, and measuring any subsequent swelling 72 
hours later.  It is known as the Tuberculin skin test (TST). The comparative intradermal 
tuberculin tests with bovine and avian tuberculin is used to differentiate animals infected with 
M. bovis and those sensitized to tuberculin due to exposure to other mycobacteria or related 
genera.  
c) Blood based test: gamma-interferon assay (ELISA) and lymphocyte proliferation assay which 
measure cellular immunity, and indirect ELISA, which measures humoral immunity. They are 
usually used as ancillary tests to maximize the detection of infected animals or to confirm or 
negate the results of the intradermal test.  
• Most commonly used in low & middle income countries: 
a) At field level: the hypersensitivity test (with tuberculin provided by the national laboratory). 
• Main challenges in diagnostics: 
a) The most commonly used test, the hypersensitivity test has some important challenges: 
o Tuberculin has become more difficult to obtain, and its availability and quality has become an 
issue. Shortages are not rare: 
http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=973  
o Technical issues with tuberculin: low degree of standardization, imperfect test accuracy, 
variations due to tuberculin doses, PPD preparation, site of application, etc…Tuberculin should 
be standardized in terms of activity for in vivo and in vitro detection assays.  
o Implementation issues: difficulties in administration and interpretation of results, need for a 
second-step visit 72 hours later for the reading.  The genetic background of the animal can also 
influence the reaction to tuberculin [7]. 
o It is not a DIVA test, allowing differentiation between vaccinated and infected animals. Up to 
80% of BCG vaccinated calves have been shown to react in the tuberculin test 6 months post-
vaccination [8]. Encouragingly, this decreased to 10-20% by 9 months’ post-vaccination and 
protection against TB was not dependent on maintenance of a tuberculin skin test response.  
o The standard TST is estimated to be able to detect around 40-80% of infected animals. 
b) The sensitivity of serodiagnostic tests needs to be increased. 
• Recent developments: (note: an exhaustive review hasn’t been done, as it is not the focus of this 
monograph). 
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a) Probably one of the most important recent developments are the DIVA tests. They have been 
developed using antigens from the MTBC which are not expressed or secreted by BCG and can 
be used instead of bovine PPD in the skin test [9] or in the whole blood IFN-γ release assay [10]. 
The first two antigens used in DIVA tests were the early secreted antigen target 6 kDa protein 
(ESAT-6) and culture filtrate protein 10 (CFP10) which are encoded in the RD1 of M. bovis and M. 
tuberculosis (not present in BCG). A further protein, Rv3615c (not secreted by BCG), and more 
recently Rv3020c were added to DIVA tests to enhance sensitivity, while not being recognised by 
non-infected or BCG-vaccinated cattle.  A recent assessment of the whole blood IFN-γ DIVA test 
incorporating ESAT-6, CFP10, and Rv3615c antigens was undertaken in 75 BCG vaccinated, M. 
bovis-infected cattle and 179 BCG-vaccinated, non-infected animals, revealing estimates of 96.0 
% sensitivity and 95.53 % specificity.  
A recent publication described the display of these antigens on polyester inclusions beads in 
order to decrease the concentration of antigen needed, and the cost.  Polyester beads 
simultaneously displaying all four proteins were produced in a single fermentation process, and 
polyester beads displaying three or four mycobacterial proteins were shown to have high 
sensitivity for detection of M. bovis-infected cattle and induced minimal responses in animals 
exposed to environmental mycobacteria or vaccinated with BCG [11].  This research has been led 
by AgResearch (New Zealand) http://www.agresearch.co.nz/news/international-interest-in-nz-
tb-test/. Dr Buddle commented that they are hoping that commercial production for the new 
skin test reagent would commence in the next 6-12 months, but it may be possible to supply the 
skin test reagent at an earlier time-point.  For more details, see information from Dr Buddle in 
Section 7. Other methods for a cocktail-based serological diagnosis have been developed, like 
the mulit-antigen print immunoassay (MAPIA). 
http://www.ncbi.nlm.nih.gov/pubmed/23038072  
b) Worldwide, M. bovis strain AN5 is used for bovine tuberculin production, but commercially 
available tuberculins differ greatly in their quality.  Attempts are being made to improve their 
quality, for example, a new lymphocyte proliferation assay for potency determination of bovine 
tuberculin PPD has been recently published. http://www.ncbi.nlm.nih.gov/pubmed/25935213  
c) Alternative tools to read out the skin test like infrared thermography have also been evaluated 
[12].   
d) ELISPOT: Xu et al have established an ELISPOT for bovine interferon-gamma (BoIFN-γ), and 
applied it in the diagnosis of bovine tuberculosis (bTB).  
http://www.ncbi.nlm.nih.gov/pubmed/26062340  
e) The indirect ELISA produced by IDEXX, and the gamma interferon ELISA produced by Prionics AG, 
have been registered by the OIE. The first one in 2012, and the later in 2015. 
http://www.oie.int/our-scientific-expertise/certification-of-diagnostic-tests/the-register-of-
diagnostic-tests/ For more details on the IDEXX test: 
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• Main needs for diagnostics: 
a) A DIVA field test that differentiates vaccinated animals from infected ones. 
b) A field test that could be read at a shorter interval, avoiding a second visit. 
c) Cheap diagnostic assays with superior sensitivity in comparison to the skin tests.   
d) There is evidence that zoonotic tuberculosis is increasing due to Mycobacterium bovis in areas 
where M. bovis is endemic. Tuberculosis caused by M. bovis requires a different treatment.  A test 
that could differentiate M. tuberculosis from M. bovis would be of relevance for physicians.  
• Differential diagnosis:  
Bovine TB should be differentiated from Contagious bovine pleuropneumonia, Pasteurella  or  
Corynebacterium pyogenes pneumonia, aspiration pneumonia, traumatic pericarditis, caseous 




M. bovis can infect humans, primarily by the ingestion of unpasteurized dairy products but also in aerosols and 
through breaks in the skin. Raw or undercooked meat can also be a source of the organism. M. bovis in humans 
is usually an accidental dead-end host. Person-to-person transmission is rare in immunocompetent individuals, 
but M. bovis has occasionally been transmitted within small clusters of people, particularly alcoholics or HIV-
infected individuals. Rarely, humans have infected cattle via aerosols or in urine.  
M. bovis used to be a significant cause of human TB, primarily in children who consumed raw milk. It decreased 
markedly following the introduction of pasteurization and meat-control practices. Bovine TB is now rare in 
humans in developed countries due to the eradication and control programs. Unfortunately, is still common in 
less developed countries, which generally lack bovine TB control programs and where exposure to infected 
animals or consumption of non-pasteurized products is expected to be more frequent.  
TB caused by M. bovis in humans is much less common than TB caused by M. tuberculosis, and the estimated 
prevalence of cases caused by M. bovis in Europe today has fallen considerably from the 30% recorded before 
the introduction of milk pasteurization procedures and “test and slaughter” control programs in cattle. It is 
difficult to discern the true global load of human TB caused by M. bovis, because TB caused by M. tuberculosis 
and TB caused by M. bovis are indistinguishable clinically, radiologically, and histopathologically. Additionally, 
there is a lack of local diagnostic capacity to detect extra-pulmonary TB, the major form of bTB in humans.  The 
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only way to determine the role of each pathogen is to identify isolates to species level. However, isolation and 
confirmatory culture of the pathogen is not routinely performed in the regions where human infections by M. 
bovis are more prevalent, thus making identification to species level problematic. M. bovis is also expected to be 
underdetected when it coinfects a person already infected with M. tuberculosis. Although thought to be 
infrequent, coinfection with M. bovis was detected in 3 of 189 TB-infected patients (1.6%) in a prevalence study 
carried out in an urban area of Brazil between 2008 and 2010. Consequently, the figure provided by the World 
Health Organization (M. bovis was responsible for 3.1% of all TB cases in humans) may not reflect the real 
dimension of the problem [13]. For more details, please see Section 3c, and for the impact see Section 4. 
Differentiation of TB caused by M. bovis is relevant, as M. bovis is naturally resistant to a major anti-TB drug, 
pyrazinamide, one of the four first-line anti-tuberculosis drugs [14] and prognosis is often poor. 
In addition to M. bovis, other members of the MTBC can also infect humans and therefore become involved in 
zoonosis. M. caprae is the causal agent of caprine TB. Exposure can be airborne or through ingestion of 
contaminated dairy products. It is widely distributed in Europe, and it is responsible for 13–31% of the zoonotic 
TB cases.  The incidence of zoonosis by M. caprae is lower than that of zoonosis by M. bovis.  
M. microtti infects small rodents, such as voles, wood mice, and shrews, and its prevalence varies (from 9% to 
31%) depending on the season and country. Zoonosis caused by this entity is rare.  M. pinnipedii is the causal 
agent of TB in pinnipeds such as seals and sea lions, and as a zoonotic agent has only rarely been described.  
 
There are several organizations dealing with TB research in humans. Some examples: 
o The global fund: http://www.theglobalfund.org/en/tuberculosis/ 
o TB alliance: http://www.tballiance.org/rd/scientific-vision .  Dedicated to the discovery and development 
of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. 
o WHO:  http://www.who.int/immunization/research/development/tuberculosis/en/   
o WHO TB facts: http://www.who.int/mediacentre/factsheets/fs104/en/   
o Stop TB partnership: http://www.stoptb.org/   
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Although bovine tuberculosis was once found worldwide, control programs have eliminated or nearly eliminated 
this disease from domesticated animals in many countries. Nations currently classified as tuberculosis-free 
include Australia, Iceland, Denmark, Sweden, Norway, Finland, Austria, Switzerland, Luxembourg, Latvia, 
Slovakia, Lithuania, Estonia, the Czech Republic, Canada, Singapore, Jamaica, Barbados and Israel.  
Eradication programs are in progress in other European countries, Japan, New Zealand, the United States, 
Mexico, and some countries of Central and South America. Although bovine tuberculosis has been eradicated 
from the majority of U.S. states, a few infected herds continue to be reported, and a few states may periodically 
lose their disease-free status. In particular, a focus of infection in wild white-tailed deer has complicated 
eradication efforts in Michigan. Similar problems exist with infected badgers in the U.K. and Ireland, and infected 
brush-tailed opossums in New Zealand.  
Bovine tuberculosis is still widespread in Africa, parts of Asia and the Americas, and some Middle Eastern 
countries. 
 
Incidence bovine TB data by country 
There are two main sources, OIE and AU-IBAR (which includes only Africa), but data are not always similar.   
1- Source: OIE.   
Data of outbreaks reported to the World Animal Health Organization (OIE) are shown in Tables 2 and 3.  Data are 
not always reliable, as many countries doesn’t seem to report, or to be reporting consistently over time.  
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail. Similar information but 
presented in a different manner can be seen in Annex 1.  Number of cases reported to the OIE by disease and by 
country: -  No information,  +   Present but quantitative data not known,   ?  Disease suspected 
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Table 2: ASIA – Bovine TB outbreaks notified to OIE from the Asian countries of interest. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Bangladesh - - + + + + + + + + - 
India + + + + + + + + - - - 
Indonesia + + - 0 - - - - - - - 
Myanmar + >3 6 5 3 1 >3 + 1 0 - 
Nepal 0 0 0 0 + 3 0 0 0 0 - 




Table 3: AFRICA – Bovine TB outbreaks notified to OIE from the African countries of interest. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso >1 + + + + + + 0 + + + 
Ethiopia + + + + + + + + 0 0 - 
Ivory Coast + 0 0 >3 18 >12 24 + >13 >5 + 
Kenya - - - - ? 0 >1 + 0 0 0 
Madagascar + + + + + 7 2 4 1 3 1 
Malawi + + + + + + + + - - - 
Mali + + + - + - - - - - - 
Mozambique 2 >3 12 19 15 33 21 14 36  >21 - 
Rwanda - 0 + + + + + + ? - - 
Senegal - - - - - - - - ? >1 + 
South Africa 28 6 12 9 33 46 37 >19 36 19 - 
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Tanzania +? +? +? 0 + + >2 + + + + 
Uganda + ? ? ? ? ? + + + + - 




The OIE, also includes zoonoses data. The number of human cases and deaths are reported by the countries. Data from the 
countries of interest, can be seen in Table 4 below. 
http://www.oie.int/wahis_2/public/wahid.php/Countryinformation/Zoonoses  
 




C: Cases,  D: Deaths 
 
2- Source: AU-IBAR. 
The African Union Inter-African Bureau for Animal Resources also has a notification system. Data are published 
in the Pan African Animal Resources Year Books. (http://www.au-ibar.org/pan-african-animal-resources-
yearbook?showall=&limitstart=). Similarly to the OIE, many countries do not seem to consistently report the 
outbreaks. Note that the number of outbreaks reported often does not match those reported to the OIE. 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Bangladesh
India C: +, D: + C: +, D: + C: +, D: +
Indonesia
Myanmar
Nepal C: +, D: +
Vietnam C: +, D: +
Burkina Faso C: +, D: +
Ethiopia C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D:+
Ivory Coast C: +, D: +
Kenya C: 2,694, D: 869 C: 2,443, D: 0 C: 1,575, D: 60 C: +, D: + C: +, D:+ C: +, D:+
Madagascar C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: +
Malawi C: 20,926 C: +, D: +
Mali C: +, D: + C: 4,734, D:0 C: 4,854, D: 248 C: 5,573, D: 462 C: +, D:+
Mozambique C: +, D: + C: +, D: +
Rwanda C: +, D: + C: +, D: + C: +, D: + C: +, D: +
Senegal
South Africa C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D:+
Tanzania C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D:+
Uganda C: +, D: +
Zambia C: +, D: +
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Table 5: Number of bovine TB outbreaks per year as reported to AU-IBAR and published in the Pan African 
Animal Resources YearBook. NS= Not specified  
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso            
Ethiopia       1     
Ivory Coast    4 39 10 24     
Kenya  1      144  2  
Madagascar   2 1 NS  4     
Malawi  1 18    34 1    
Mali     1       
Mozambique  6 6 2 15 2 7  2 2  
Rwanda            
Senegal          1  
South Africa  6 15 16 5 37 37 9 36 23  
Tanzania   6    1 10    
Uganda    1 1 4 9 10    
Zambia   1 4 5 5 3 16 10 6  
 
2005: Bovine TB was not included in the 2005 report. 
2006: Most African countries do not do routine diagnosis for bTB, and the reported cases are usually from the 
slaughterhouse.  
2008: The outbreaks of bTB mainly affected cattle (77.3%). 20.3% of the outbreaks were unspecified, ovine were involved 
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Prevalence bTB data by country (from 2000 onwards) 
• Sources: PubMed, and internet engine searches (English and French when applicable).   
• Efforts have been made to include the year of the study, and not the year of the publication. If they are 
known to be different, the year of publication is included in the reference.  
• For grey literature, links have been included when possible.   
• Note that not all papers have been read in full. In many cases, only the abstracts have been read. Critical 
evaluation of the papers for inclusion has not been conducted.  
• Humans: Please see section C for total human TB cases and for zoonotic TB reports from Africa and Asia.  
If data for zoonotic TB has been found for a specific country, it has also been included under the country 
in this section.  
A report published by ILRI in 2012 (Mapping of poverty and likely zoonoses hotspots - 
https://cgspace.cgiar.org/bitstream/handle/10568/21161/ZooMap_July2012_final.pdf), based on a systematic 
literature review of the last 10 years for Africa, South Asia and South East Asia (also some studies from the 
Middle East were included), found that overall 7.4% of livestock were positive. Overall prevalence was: bovines 
8%, camels 11%, shoats 2%, pigs 15% and wildlife 5%.  (Note: it is referred as prevalence in developing countries, 
but based on the methodology described, not all the developing countries have been included).  




Figure 2: Tuberculosis prevalence in countries included in ILRI 2012 report on “Mapping poverty and likely 
zoonoses hotspots” 
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Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 

















Sirajganj district Cattle 270 Antigen Rapid Bovine 
TB Ab test: 7.78 
Mahmud et al, 
2014  




2012 Mymensingh Sadar Cattle 101 Antigen Rapid Bovine 
TB Ab test: 5.94 
Hoq Mondal, 2012  
2012 Bangladesh livestock 
research institute* 






All suspicious cases 
proved false positives 
Hassain, 2012  
2009-
2011 
Dhobaura upazila of 
Mymensigh district 
Cattle 649 Caudal skin test 
2.34 
Sarker et al, 2015  
*:  Even if the authors extrapolate the data to national prevalence, it is questionable that results from one farm 
can be translated at national level, as there is no enough data. However, it is a good start.  
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**: Note that the paper mentions 33.73% but calculations do not seem correct. 37 positives out of 150= 24.7%. 
Humans: 




Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2010 Himachal Pradesh Cattle 440 Individual: 14.31 
Herd: 16.67 
Thakur et al, 2011  
2008 North India Cattle 768 from 
suspected positive 
farms 
54 isolates were 
identified.  
M. bovis: 40 isolates 




* Study not indicative of prevalence, but confirms infection of cattle with M. tuberculosis 




Data from Danish Ali and Bhoj R Sing, Division of Epidemiology, IVRI, Izatnagar, India. Published on June 2015: 
http://www.slideshare.net/singh_br1762/bovine-tuberculosis-epidemiology-control-in-india  
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In 2010, Jain reported that out of 155 patients enrolled as suspected extra-pulmonary TB, 147 were PCR positive 
[15]. Of those, 85.71% were PCR positive for M. tuberculosis, 9.52% for M. bovis, and 4.76% were coinfections of 
the two.  
 
Indonesia 
No information was found. 
 
Myanmar 
No information was found.  
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Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2012  Buffaloes and 
cattle 
 Buffaloes: 9.08 
Cattle: 5.78 
Joshi et al, 2012* 
2012 Animals reared by TB 
infected persons 




Western Chitwan Cattle and 
buffaloes 
100 Cattle: 13.6 
Buffaloes: 15.4 
Pandey et al, 2012  
2004  Cattle and 
buffaloes 
 5 Pun et al, 2004** 
*: Paper not available, but data mentioned by Dhakal, 2013.  
 **: Paper not available, but data mentioned by Jha et al, 2007. 
• Humans: 
Gurung et al, 2010: EPTB accounts for 10-15% of call cases of TB. From a total of 513 patients with EPTB, 54 
were culture positive.  On characterization of the isolates, 48 (88.9%) were identified as M. tuberculosis, 4 as M. 




A serological study in 2004 of 1,201 dairy cattle, reported negative results for M. bovis (as mentioned by 
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Year Area Species of 
animal 






1,499 6.8 Tarnagda et al, 
2014  
2012 Ouagadougou Dairy cattle 1,420 6.05 Boussine et al, 
2012  
2004 Hamdallaye Dairy cattle 325 27.7 Traore et al, 2004  
1999 Bobo-
Dioulsasso 
Bovines a) 174 from 6 herds 
 
b) 64 milk samples 
 
c) 199 slaughtered 
animals 
d) Meath inspection 
records: 4,525 
a) 13% positive, 16% 
indeterminate. Only one 
herd negative out of 6. 
b) 26.5% positive culture 
for M. bovis 
c) 19% lesions suggestive 
TB., and from those, 47% 
were positive to M. bovis 
d) 10% 
Vekemans et al, 
1999  
 
Sanoue et al, 2014, report the genotyping of M. bovis isolated from cattle and humans, and concluded that M. 
bovis circulates between Burkina Faso and its neighbouring countries, and that M. bovis is transmitted mainly 
between cattle, but also between cattle and humans.  
Humans: 
Godreuil et al reported in 2007 a study on 120 Mycobacterium isolates from patients with pulmonary TB, none 
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Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2013 Addis Ababa 
municipal abattoir 
Cattle 500 Post mortem: 5 




2012 Central Ethiopia Cattle 2,033 cattle from 
287 herds 
Individual: 1.8 (4 mm cut off), 
and 4.7 (2 mm cut off) 
Herd: 9.4 (4 mm cut off) and 
20.2 (2 mm cut off) 
Ameni et al, 
2013  
2011 Akaki and Metehara 
abattoirs 




50 Km radius Addis 
Ababa 
Dairy cattle 2,956 animals 
from 88 herds 
Small farms (1-10 animals):  
Individual: 9.2 
Herd: 23.5 








al, 2012  
2008-
2010 
Negelle, Filtu, Mojo 








Cattle: 50 out of 
5,250 
Camels: 81 out of 
694 
Goats: 76 out of 
1,744 
Culture positive: 
Cattle: 36 out of 50 
 
Camels: 3 out of 81 
 
Goats: 9 out of 76 
Gumi et al, 
2012  
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406 (63 goats, 
343 sheep) 
4 and 2 mm cut off used: 
Cattle:  1.6 (4 mm) and 6.8 (2 
mm) 
SR: 0 (4mm), and 0.41 (2 mm) 
Tschopp et 









Cattle: 0.8 (4 mm cut-off) and 
3.4 (2 mm cut off). Herd 
prevalence was 33.3 and 83 
with the same cut-offs.  
Goats: 0 
Tschopp et 
al, 2010  
2006-
2008 
Abattoirs in Gonder, 
Woldiya, Gimbi, 
Butajira and Jinka 




Hawassa town and 
surroundings 
Cattle 413 Individual: 11.6 
Herd: 48.7 









72 milk samples 
15.7 (Higher when owned by 
TB patients) 
25% milk samples TB positive. 
Fetene et al, 
2008  
2007 Selalle and Holeta Cattle 5,424  13.5 Ameni et al, 
2007  
2007 Adama Town, 
Central Ethiopia 







Oromia, Amhara and 
Southern Nations 
Cattle 2,216 from 73 
villages 
Meskanena Mareko: 7.9 
Woldia: 1.2 
Bako Gazer: 4.3 





al, 2009  
2004-
2005 
Central Ethiopia Cattle 1,041 Owners with active TB: 24.3 Regassa et al, 
2008  
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Owners with no TB: 8.6 
2004 Addis Ababa abattoir Cattle 1,350 1.5 Asseged et 
al, 2004  
2004 Hossana municipal 
abattoir 









780 Individual: 4.1 
Herd: 51 
Laval and 
Ameni, 2004  
1975-
2006 
Literature review Cattle  Range 3.4% (small holder 
production system) to 50% (in 
intensive dairy productions). 
Range of 3.5% to 5.2% 
(slaughterhouses in various 
places of the country) 
Shitaye et al, 
2007  
*: Prevalence is difficult to calculate, as only culture data is given. The paper focus more on the typing of the 
isolates. 
Humans: 
The majority of the publications do not cover prevalence of zoonotic TB, but the proportion of M. bovis isolates 
from human cases.  
• Getahun et al 2015, reported that 92 isolates collected between 2010 and 2011 were all M. tuberculosis.  
Most of the isolates were collected in rural and pastoralist population where raw milk consumption is 
widely practiced, therefore, the absence of M. bovis was unexpected and contradicted earlier studies. 
The fact that eligible individuals were selected on signs of pulmonary TB, and M. bovis tends to produce 
EPTB, might have influenced the results.  
• Korma et al 2015, reported that out of 200 cases of suspected EPTB in Addis Ababa, they obtained 59 
cultures and only one was M. bovis (1.7%).  
• Nuru et al 2015, reported that out of 168 isolates from Bahir Dar City (Nortwest Ethiopia), 2 (1.19%) 
were M. bovis. Both were isolated from TB lymphadenitis cases.  
• Seyoum et al 2014, characterized EPTB in Dera Woreda, North Showa, and out of 145 cases, only 1 
(0.9%) was positive for M. bovis.  
• Firdessa et al, 2013 mentions that in Ethiopia, 33% of all new TB cases are EPTB (while the global 
average is 15%). Out of 964 cultures from patients recruited between 2006-2010, only 4 (0.4%) were M. 
bovis, and all were isolated from pulmonary TB.  
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• Gumi et al 2012, reported that in a study conducted 2008-2010 in Oromia and Somali Regional States in 
pastoral and agro-pastoral communities, out of 163 isolates, only 3 were M. bovis, and all of them were 
from pulmonary TB.  
• Beyene et al, 2009 looked at 156 cultures from patients with EPTB, and no M. bovis was identified.  
• Fetene et al, 2008 reported that M. tuberculosis (74.5%), M. bovis (14.9%) and atypical mycobacteria 
(8.5%) were identified from sputum and fine needle aspiration specimens of tuberculosis patient cattle 
owners in Western Gojam in 2007-2008. 5% of M. bovis were identified in cases of pulmonary TB, and 8% 
in cases of EPTB.  
• Kidane et al, 2002, performed PCR in 35 EPTB samples from Southern Ethiopia, and found 6 (17.1%) to 




Year Area Species of 
animal 





Various 17,279 condemned 






Cisse et al, 2008  
 
Humans:  
Dosso et all in 1996, during a national surrvey conducted in 1995-1996 noted that out of 320 humans tested, 0 




Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2009 Two abattoirs in 
Nairobi 
Cattle 929 19% lesions 
3.7% culture 
Kuria and 
Gathogo, 2013  
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2007 Dagoretti Dairy Cattle 143  
 









Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2015 Antanifotsy 
(Vakinankaratra) 
Dairy cattle 429 Doubtful: 0.9% 
The rest negative 
La Gazette de la 
Grande Ile  
1996  Cattle  6.5 Rasolofo-
Razanamparany, 
1999  





















Ssartirano et al 
 
Humans:  
• Rasolfo Razanamparany et al 1999, reported that the prevalence of M. bovis in 1994-1995 was 
determined at 1.25% for PTB, and 1.3% for EPTB in urban areas.  
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• Menard et al 1995, reported that out of 138 strains isolated from EPTB patients in Antananarivo, only 1 
(0.73%) was M. bovis. 
• Rasololofo-Razanamparany et al 1995, reported that in Antananarivo, out of 126 strains isolated from 
pulmonary TB cases at the Institut d'Hygiene Sociale, 3 (2.38%) were M. bovis.  In the prison, out of 36 




Year Area Species of 
animal 
No. of samples tested % positive Reference 
2011 Mzimba and Nkhata 
Bay (Northern 
region) 
Cattle 95 cows from 74 farms 1.1 Tebug et al, 2014  
1986  Cattle 2,032 from dip tanks 
1,449 dairy cattle 





Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2007 Abattoir Bamako Cattle 3,330 Lesions: 1.8 Muller et al, 2008  
2001-
2003 
Bamako and Mopti 
abattoirs 




Dao, 2005  
2002-
2003 
Peri-urban Bamako Dairy cattle 1,087 Skin test: 18.58 Sidibe et al, 2003  
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Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 








Bovigam IFNγ test: 0 
ELISA: 0 
 
Cattle (skin test): 
Inside park: 0.5 
Outside park: 1.3 
Tanner et al, 2015  
2014 Govuro District 
(Southeast) 
Cattle 1,136 from 289 
farmers 
39.6 Moiane et al, 2014  
2008 Govuro district Cattle 268 61.94 Macucule, 2009  
 
Humans:  








% positive Reference 
2009 Abattoirs of 
Nyabugogo-
Nyabugogo, Kigali 
Cattle 16,753 Lesions: 0.9 
 






169,488 Eastern Province: 11.8 
Northern Province: 3.2 
Nshimiyimana et 
al, 2013  
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Southern Province: 2.8 
Western Province: 2.9 
Kigali Capital city: 1.4 
See Table and Figure below 
for details 
Bovine TB prevalence [5] from 2006 – 2010 by district and provinces of Rwanda.  Source: Nshimiyimana et al, 
2013 
 
Progression of the prevalence of bovine TB by province in 5 years period 
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Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2005-
2008 
Dakar abattoirs Cattle 200,101 0,0185 
(37 animals, and 30 
were from Mali, one 
from Mauritania, and 
only 6 from Senegal) 
Diagne, 2009  
2000-
2003 
Kaolack and Fatick Cattle 479 Doubtful: 1.04 Konte and Unger, 
2003 (mentioned 
by Diagne, 2009) 
 
Humans:  
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Year Area Species of 
animal 
No. of samples 
tested 




National Park complex 
Cattle 1,166 Positive: 0.34 
Inconclusive: 2.74 
Musoke et al, 2015  
2011 Hluhluwe-iMfolozi 
Park 
Buffaloes 19 PCR: 42.1 
Stains: 36.8 





Buffaloes 4,733 2.3 – 54.7 Ie Roext et al, 
2015  
1995 Molopo district (North 
West Provine) 


















Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2011 Serengeti ecosystem Indigenous 
cattle 
1,103 from 32 
herds 
Individual: 2.4 by skin test 
(true prevalence: 0.6) 
Katale et al, 2013  
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Cattle 1,288 3.7 Mwakapuja et al, 
2013  
2007 Manyara region Cattle 10,549 0.9 
Herd prevalence: 11.8 
Cleaveland et al, 
2007  
2004 Kibaha and 
Morogoro 








Arusha municipality Cattle  Lung 
condemnation 
out of 115,186  
0.7 Mellau et al, 2010  




Durnez et al, 2009  
2003-
2004 
Tanga region  Cattle 642 5.4 
Smallholder dairy: 2 
Traditionally managed: 0 
Swai and 
Schoonman, 2012  
2003-
2004 







Milk: one isolate M. 
tuberculosis (no M. bovis) 
Karimuribo et al, 
2005  
2003 Eastern Tanzania 
(Morogoro, Coast 
and Dar-es-Salaam) 








Shirima et al, 2003  
2002-
2004 
Tanga city abattoir Cattle 12,444 0.32 Swai and 
Schoonman, 2012  
2001 Southern highlands Cattle  Ind: 13.2 
Herd: 51 
Kazwala et al, 
2001  
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1998 Southern highlands Milk 
samples 
805 M. bovis isolated in 0.25% 
(2 samples) 
Kazwala et al, 
1998  
1997 Lake Victoria zone Cattle 8,190 0.2 
 
Jiwa et al, 1997  
 
A summary is also given by Katale et al, 2012. 
Humans:  
• Katale et al, 2015. Out of  472 TB suspected patients, no M. bovis was isolated.  
• Cleaveland et al 2007, reported that M. bovis was confirmed in seven out of 65 (10.8%) human cervical 
adenitis cases (EPTB), of which only one came from a household owning infected cattle. 
• Kazwala et al 2001, reported that out of 44 isolates from all forms of TB, 7 (16%) were identified as M. bovis. 
• Mfinanga et al, 2004, in their study in Arusha, out of 65 cultures from EPTB cases in Arusha region during 
1999-2001, M. bovis was isolated in 10.8% of the cultures. 
• Daborn et al, 1997, out of 19 lymph node biopsies (suspected EPTB), 4 (21%) showed M. bovis (as referenced 




Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2014 Kashaari county 
(Mbarara District) 





Herd prev: 14.28 
Kazoora et al, 
2014  
2012 Mubende district Pigs Approx 1,000  M. bovis isolated from 3 
out of 150 suspicious 
lymph nodes 
Muwonge et al, 
2012  
2009 City abattoir Cattle 16,800 Lesions: 0.5 Asiimwe et al, 
2009  
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Cattle 37 herds, 50 












Cattle 1,864 51.4 Oloya et al, 2006  
2002 Mbarara Dairy cattle 340 herds Indiv prev: 6 
Herd prev: 74.1 
Bernard et al, 2005  
 
Humans:  
• Assimwe et al, 2008, found that out of 344 isolates of TB patients attending clinics in Rubaga district, only 1 
(0.29%)was confirmed M. bovis.  
• Oloya et al 2007, reported that out of 43 biopsies (EPTB) from patients at Matany and Moroto hospitals in 
Karamoja, 3 (7%) were M. bovis.  
• Byarugaba et al 2005, reported that out of 69 cultures from patients at the Mbarara University teaching Hospital, 
none was M. bovis.  





Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2012-
2013 
Namwala district Cattle 96 herds Herd: 36.4 
Individual: 0-14 
Tembo, 2013  
2012 Namwala abattoir Cattle 1,680 Lesions: 7.4 Munyeme et al, 
2012  
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from PPD + 
1,025 cattle 






3 milk samples (18.7%) 
positive for M. bovis 
Pandey et al, 2013  
2009 Livestock/ wildlife 
interface  
Cattle 994 from 111 
herds 
Lochinvar: 5.2 
Blue Lagoon: 9.6 
Kazungula: 0.8 
Munyeme et al, 
2009  
2008 Southern Province Cattle 
traditionally 
reared 
459 4.8 Muma et al, 2013  
2004-
2008 
Kafue basin Kafue lechwe 119 Lesions: 24.3 Munyeme et al, 
2010  
2006 Western Province Carcass 
condemnation 
32,717 0.46 Phiri, 2006  
2003-
2004 
Kafue basin Cattle 106 herds 49.8 Munyeme et al, 
2008  
1996 Monze District Cattle 2,226 Individual: 7.4 
Herd: 33 
Cook et al, 1996  
 
Humans:  
Malama et al 2014, looked at 55 isolates obtained from PTB cases in Namwala district in 2011-2012, and 2 
(3.6%) were identified as M. bovis. 
  
Human prevalence and incidence data for TB and zoonotic TB 
Table 6 shows the incidence and prevalence for TOTAL tuberculosis in humans for the focus countries.  The 
majority of cases will be due to M. tuberculosis and not M. bovis. It was believed that 3.1% of the total cases of 
TB, were zoonotic TB. Please see Section 4 (human impact) for more details.  
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There are 22 countries that are classified as “High burden TB countries”. They include 11 of the IDRC focus 
countries, and more data is available for those countries (first half of Table 6).  However, the incidence per 
100,000 population is very high for some of the other focus countries, such as Zambia, Malawi and Madagascar.   






From a review of a number of zoonotic tuberculosis studies, published between 1954 and 1970 and carried out 
in various countries around the world, it was estimated that the proportion of human cases due to M. bovis 
accounted for 3.1% of all forms of tuberculosis: 2.1% of pulmonary TB (PTB) and 9.4% of extra-pulmonary TB 
(EPTB) [16].  Ingestion of raw dairy products from infected cattle, is more likely associated with the development 
of EPTB. However, those estimates were thought not to reflect the reality due to the difficulties in correct 
Country TB Mortality Prevalence Incidence Population
Incidence per 100,00 
2014*
Bangladesh 81,000 640,000 360,000 159,078,000 227
Ethiopia 32,000 190,000 200,000 96,959,000 207
India 220,000 2,500,000 2,200,000 1,295,292,000 167
Indonesia 100,000 1,600,000 1,000,000 254,455,000 399
Kenya 9,400 120,000 110,000 44,864,000 246
Mozambique 18,000 150,000 150,000 27,216,000 551
Myanmar 28,000 240,000 200,000 53,437,000 369
South Africa 24,000 380,000 450,000 53,969,000 834
UR Tanzania 30,000 270,000 170,000 51,823,000 327
Uganda 4,500 60,000 61,000 37,783,000 161










All Data from: http://www.tbfacts.org/tb-statistics/
Except *: http://data.worldbank.org/indicator/SH.TBS.INCD 
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diagnosis (see Zoonotic disease in Section 2).  Some other reports have speculated that M. bovis accounts for 10 
to 15 percent of human tuberculosis cases [16], while other estimates range from 0.4 to 8 % [17].  
The ILRI Report 212 already mentioned (Mapping of poverty and likely zoonoses hotspots - 
https://cgspace.cgiar.org/bitstream/handle/10568/21161/ZooMap_July2012_final.pdf) concluded that on 
average, 10.5% of the human TB cases were associated with M. bovis.   
 An attempt to estimate the global occurrence of zoonotic TB caused by M. bovis or M. caprae infections in 
humans by performing a systematic review and analysis of relevant scientific literature of the last 2 decades, was 
conducted by Mueller et al in 2013 [18].  Although information from many parts of the world was not available, 
data from 61 countries suggested a low global disease incidence. In regions outside Africa included in the study, 
overall median proportions of zoonotic TB of ≤1.4% in connection with overall TB incidence rates ≤71/100,000 
population/year suggested low incidence rates. For countries of Africa included in the study, the observed 
median proportion of zoonotic TB cases of 2.8% was multiplied with the continental average overall TB incidence 
rate of 264/100,000 population/year, which resulted in a crude estimate of 7 zoonotic TB cases/100,000 
population/year. It is to note that the study found no data for Southeast Asia, including major cattle producing 
middle- and low-income countries (e.g., India, Bangladesh, Pakistan, Myanmar, Indonesia) as well as others like 
Kenya, South Africa and Sudan.  The authors acknowledged that the results were influenced by the technical 
constraints, specifically diagnostics and therefore, TB caused by M. bovis may be systematically underreported.   
Table 7 summarizes the data presented by Mueller 2013 [18] and by the ILRI 2012 report.  
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Table 7: Studies on the proportion of zoonotic TB.  Modified from Mueller 2013 [18] and the ILRI 2012 report 
(link provided in the text above). Updated with all recent and /or additional references mentioned under 
each country in section 3b. Note it does not include updated references for non-focus countries.  




Country Study Location Year MTBC M. bovis %
Burkina Faso Health centers in Ouagadougoou and Bobo Dioulasso PTB 2001 120 0 0.00%
Burundi Bujumbura, Bubanza Hospital Both 1987-1994 170 0 0.00%
Cameroon 15 District hospitals West PTB 1997-1998 455 1 0.22%
Chad Chari-Baguirmi Both 2002 10 0 0.00%
Djibouti Unknown 2002 85 1 1.18%
Egypt Fever hospital in cities 2002 67 1 1.49%
Ethiopia Rural and pastoralist areas PTB 2010-2011 92 0 0.00%
Ethiopia Addis Ababa EPTB 2015 59 1 1.69%
Ethiopia Bahir Dar City (Nortwest) EPTB 2012-2014 168 2 1.19%
Ethiopia Dera Woreda (North Showa) EPTB 2014 145 1 0.69%
Ethiopia NA PTB 2006-2010 964 4 0.41%
Ethiopia Oromia and Somali regions PTB 2008-2010 163 3 1.84%
Ethiopia Butajira hospital EPTB 2005-2006 156 0 0.00%
Ethiopia Western Gojam PTB 2007-2008 5.00%
Ethiopia Western Gojam EPTB 2007-2008 8.00%
Ethiopia Southern Ethiopia EPTB 2000-2001 35 6 17.14%
Ethiopia Butajira health centre EPTB 2000-2001 35 11 31.43%
Ethiopia NA PTB NA 48 14 29.17%
Ethiopia Fitche Hospital TB clinic Both 2004-2005 42 7 16.67%
Ethiopia Felegehiwot Both 2007-2008 47 8 17.02%
Ghana Korle-Bu teaching hospital PTB 2003 64 2 3.13%
Guinea B Unknown 1999 229 4 1.75%
Ivory Coast TB and rural health centres PTB 1994-1996 320 0 0.00%
Kenya Narok 2001 132 0 0.00%
Madagascar Institut d'Hygiene Sociale, Antananarivo PTB 1994 126 3 2.38%
Madagascar Antananarivo prison PTB 1994 36 0 0.00%
Madagascar Antananarivo - urban areas EPTB 1994-1995 156 2 1.28%
Madagascar Antananarivo - urban areas PTB 1994-1995 1.25%
Madagascar Antananarivo, Antsirabe, Fianarntsoa and Mahajanga PTB 1994-1995 316 4 1.27%
Madagascar Antananarivo EPTB 1994-1995 138 1 0.72%
Malawi Blantyre, Queen Elizabeth Hospital PTB NA 30 1 3.33%
Mozambique Maputo EPTB 2013-2014 49 0 0.00%
Nigeria 2 hospitals Ibadan 2006 60 3 5.00%
Nigeria Lagos 1986 91 4 4.40%
Nigeria Jos PTB NA 65 10 15.38%
Nigeria Lagos 1989 357 3 0.84%
Sierra Leone Western Area and Kenema Districts PTB 2003-2004 97 0 0.00%
Tanzania Arusha PTB 2014 472 0 0.00%
Tanzania Arusha EPTB 1999-2001 65 7 10.77%
Tanzania NA EPTB 1997 19 4 21.05%
Tanzania Arusha 2007 34 7 20.59%
Tanzania Pastoralist Nort & South 2001 38 7 18.42%
Tanzania Arusha 2004 34 7 20.59%
Tanzania Arusha EPTB 1994 11 4 36.36%
Tanzania NA EPTB NA 53 20 37.74%
Tanzania Arusha and Southern highlands Both 1993-1996 44 7 15.91%
Tanzania Three districts Arusha region EPTB 1999-2001 65 7 10.77%
Uganda Kampala 2008 344 1 0.29%
Uganda Kampala PTB 1995-1997 234 1 0.43%
Uganda Karamoja 2007 43 3 6.98%
Uganda Karamoja EPTB NA 24 3 12.50%
Uganda Mbarara Both 2004-2005 69 0 0.00%
Uganda Kampala, Rubaga division PTB 2006 386 1 0.26%
Zambia Namwala district PTB 2011-2012 55 2 3.64%
Bangladesh Clinical 2010 350 0 0.00%
Pakistan Hospital Lahore 2012 42 5 11.90%
India EPTB hospital adjusted for prev EPTB in population EBTB 2011 155 22 2.90%
India EPTB hospital adjusted for prev EPTB in population EPTB 2005 115 53 12.60%
India TB meningitis EPTB 2006 37 24 64.86%
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Economic and Social Impacts at Global 








Bovine TB is a health problem worldwide, causing significant economic hardship for livestock farmers with 
estimates of >50 million cattle infected worldwide, costing $3 billion annually [19]. But due to its zoonotic nature, 
bTB can have serious consequences for public health.  
Financial hardships to livestock owners and farmers, and associated industry include costs associated with 
reduction in productivity in severely affected animals, testing, culling of affected animals, indemnity payments, 
movement controls, restrictions on trade, maintenance of control programs, and research to develop improved 
control strategies. 
 
Impact in Africa 
In a questionnaire survey conducted by the OIE in Africa during Dec 2014 – Jan 2015 and sent to the Veterinary 
Authorities of the 54 African OIE member countries, respondents were asked to estimate parameters that drive 
economic impacts for 35 priority diseases (including bovine TB). In all, 27 out of 54 countries provided 
quantitative information.  
(http://www.oie.int/fileadmin/Home/eng/Publications_%26_Documentation/docs/pdf/TT/2015_AFR1_Grac
e_A.pdf).  The level of responses indicated a high level of lack of information on disease impacts. Expert opinion 
was used to estimate the average value of adult livestock at USD 379 for cattle. Vaccination and treatments 
were estimated to cost USD 2 and USD 3 for large animals. Using these approximate estimates, the 35 priority 
diseases were roughly estimated to cost nearly USD 9 billion a year or 6% of the total value of the livestock 
sector in Africa. These estimates do not include losses due to lost productivity or to impacts on human health.  
The results can be seen in Figure 3, and would represent approximately USD 200 million per year for bTB. These 
results need to be taken with caution, considered the methodology described (using estimated parameters given 
by respondents) and the limitations. Caution needs to be taken. For example, looking at other diseases, Tambi et 
al reported in 2006 an annual cost of CBPP of 44.8 million euros (approx. USD 50 million) which is very far from 
the over 400 million calculated in this study.   
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Figure 3: Losses from cattle diseases, as estimated by OIE Africa.  Source: Grace, Songe and Knight-Jones, 
2015. Impact of neglected diseases on animal productivity and publich health in Africa. OIE Africa Regional 
Commission.   
 
Analysis by the World Bank: 
The World Livestock Disease Atlas – a quantitative analysis of global animal health data [20], published  by the 
World Bank (with cooperation of OIE and FAO) in 2011 is an attempt to understand which livestock diseases 
cause the heaviest losses, which countries suffers the worst disease-related losses and which livestock species 
are most affected.   
http://wwwwds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2012/02/17/000356161_201
20217030841/Rendered/PDF/668590WP00PUBL00Livestock0Atlas0web.pdf 
The World Livestock Disease Atlas bases its analysis on the Livestock Units (LSU).  Each species has a LSU value, 
and the losses of LSU have been given a value.  See Figure 4. For more information on the methodology 
description, please refer to the World Bank Atlas itself (pages 6 & 7). Bovine TB is one of the top 10 diseases 
causing losses for cattle, buffalos and small ruminants, as shown in Figure 5. However, looking at the data in 
detail, there are few data from sub-Saharan Africa and Asia.  
Bovine Tuberculosis | Monograph 15 















Figure 5: Top 10 diseases in terms of LSU losses for cattle, buffalo, and sheep & goats. Source: World 
Livestock Disease Atlas – The World Bank, 2011 [20][3]. 
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Infection of wild animals by bTB is raising concern worldwide.  Its importance relates to conservation issues 
(impact on wildlife including endangered species), impact on livestock production, impact on public health and 
economic impact on private game ranchers [21].  
Wildlife can play an important role as maintenance hosts, and interfering in the disease control, as 
demonstrated by the European badger in UK and the Republic of Ireland, and the possum in New Zealand.  
In Africa, bTB has been confirmed in livestock in the majority of countries. Wildlife infection is confirmed in 
seven countries from southern and eastern Africa, apparently spreading in the southern Africa region. M. bovis 
has been isolated from 17 wild mammal species, although maintenance host status has only been shown for 
buffalo and lechwe, and suggested for greater kudu and possibly common warthog. Buffaloes don’t seem to be 
clinically affected. It is suspected that most other wild species act as dead-end-hosts.  
Zoonotic risks are a concern, but no direct spillover from wildlife to humans has been documented, and no case 
of bTB spillback from wildlife to livestock has been confirmed.  
 
Human impact 
Prior to mandatory pasteurization in many countries, M. bovis accounted for ∼25% of TB cases in children. In 
Great Britain alone, it is estimated that human consumption of infected cows’ milk led to 2,500 deaths and 
>50,000 new cases of TB per year in the early 1900s.  At present, M. bovis infection of humans is rare except in 
developing countries that do not have control programs or mandatory pasteurization directives. 
The WHO Global Tuberculosis 2015 Report, says that 9.6 million people fell ill with TB in 2014, including 1.2 
million people living with HIV. In 2014, 1.5 million people died from TB, including 0.4 million among people who 
were HIV-positive (http://who.int/tb/publications/global_report/factsheet_global_2015.pdf?ua=1).   
Regarding the prevalence of zoonotic TB, as mentioned in Section 3c, there is a scarcity of data. A review of a 
number of zoonotic tuberculosis studies, published between 1954 and 1970 and carried out in various countries 
around the world, estimated that the proportion of human cases due to M. bovis accounted for 3.1% of all forms 
of tuberculosis Some other reports have speculated that M. bovis accounts for 10 to 15 percent of human 
tuberculosis cases [16], while other estimates range from 0.4 to 8 % [17].  More recently, a report published by ILRI 
in 2012, concluded that an average of 10.5% of human TB cases were associated with M. bovis in developing 
countries (not all developing countries were included), and Mueller et al in 2013, concluded that the proportion 
of zoonotic TB in Africa was 2.8%.  
For more details on zoonotic prevalence per country, please see section 3.  
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Disability adjusted life years (DALY’s) 
The WHO Estimates of the global burden of foodborne diseases Report, published in December 2015, 
(http://www.who.int/foodsafety/publications/foodborne_disease/fergreport/en/), estimates the Disability 




Figure 6: Scatterplot of the global burden of foodborne diseases per 100,000 population and per incidence 
case Source: WHO Estimates of the global burden of foodborne diseases, 2015. (Note: axes use log scales).  
The red arrow points at M. bovis. Green arrows point at other diseases of interest for IDRC (T. solium, 
Brucellosis and E. granulosus) 
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Cost effectiveness of control & research strategies 
Research and control efforts, however, have proven cost effective. For instance, it is estimated that the US 
bovine TB eradication program cost ∼$3.5 billion from 1917 to 1962 which resulted in a net savings of ∼$159 
million annually, primarily due to decreased carcass condemnation, improved animal productivity, and reduced 
animal replacement costs [19]. Some other authors, question the resources invested in the control of zoonotic TB, 
at least in countries like the UK [22].  
 
Country information 
Only information from Zambia was found.  Mwacalimba and colleagues [23] developed an economic simulation 
model evaluating the costs and benefits of bTB control in a wildlife-livestock interface area of Southern Zambia 
over a 10 year period.  They were based on the use of test and slaughter in livestock and promotion of milk 
pasteurization amongst livestock keeping communities to reduce the zoonotic transmission of bTB through milk. 
Expected benefits included increased productivity and health in village resident and transhumant cattle, and 
averted human bTB treatment costs after the fourth year of the project. In monetary terms, at different bTB 
prevalence estimates in cattle, the simulation outcome showed that the costs of control never exceeded the few 
benefits considered over the simulated period. However, the benefits are likely to outweigh the costs if wider 
implications of bTB in humans (infirmity-related productivity losses), livestock and wildlife (reduced productivity 
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There are four principal approaches to the control of tuberculosis: 1) test and slaughter, 2) test and segregation, 
3) Immunization and 4) Chemotherapy. Chemotherapy is forbidden in the majority of the countries, 
immunization is not very effective, so the main measures used have been test and slaughter, and test and 




Until the discovery of the antituberculosis drug isonicotinic acid hydrazide (INH), there was no practical 
therapeutic agent available for the treatment of bTB. Reports from Brazil and South Africa suggest that it is 
feasible to treat cattle with isoniazid. It is claimed a 78% bacteriological cure, and a prophylactic value. It is easy 
to administer and has relatively few adverse effects. It is used at 10mg/Kg body weight daily for eight weeks.  
As all reactors that are treated are not cured bacteriologically, INH treatment cannot be regarded as a means of 
eradicating the disease. The disadvantages are so great, however (up to 25% refractory cases, emergence of 
drug resistant strains, elimination of INH in the milk and the danger of relapse when the drug is withdrawn) that 
the treatment is not allowed in many countries.  
Treatment with INH is regarded as a temporary measure, and would only be justified where an attempt is made 




Sanitation and disinfection may reduce the spread of the agent within the herd. M. bovis is relatively resistant to 
disinfectants and requires long contact times for inactivation. Pasteurization and abattoir inspection are 
recognized as successful methods to decrease the spread of the disease to humans.  
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BCG vaccines, incorporate a culture-attenuated variant of M. bovis (Bacillus Calmette–Guérin), for the basis of a 
human tuberculosis vaccine.  The same vaccine has been used in cattle in some high-risk areas, but it does not 
completely prevent infection. For more details, see Section 6. Unfortunately, vaccinated cattle react on the 
tuberculin skin test and therefore the vaccine should not be used in countries where control or trade measures 
are based on such testing. However, this should not preclude its use, especially in developing countries where 
other measures are not feasible, unless final stages of eradication programs have been reached. Countries that 
attempted to use vaccination as the basis of a control program have ultimately abandoned the procedure in 
favor of the test-and-slaughter method.  
There are no more effective vaccines for use in livestock or wildlife. New vaccines are being developed and 
tested. For more details, see Section 8.  
 
Options and strategies for control programs at herd, national, sub-national or regional level 
The Food and Agriculture Organization of the United Nations (FAO) has recognized zoonotic bovine tuberculosis 
as a priority infectious disease which should be controlled at the animal–human–ecosystem interface, through 
national and regional efforts. 
Bovine TB can be controlled by test-and-slaughter or test-and-segregation methods. Affected herds are re-
tested periodically to eliminate cattle that may shed the organism; the tuberculin test is generally used. 
Infected herds are usually quarantined until no further reactors are detected, and there is no evidence of 
tubercules in reactors at slaughter, and animals that have been in contact with reactors are traced. Only test-
and-slaughter techniques are guaranteed to eradicate tuberculosis from domesticated animals. However, some 
countries use test-and-segregation programs during the early stages of eradication, and switch to test-and-
slaughter methods in the final stage. Once eradication is nearly complete, slaughter surveillance, with tracing of 
infected animals, may be a more efficient use of resources.  
The success of control programs based on the test and slaughter strategy depends on institutional and technical 
requirements including (as mentioned by Ahmed El Idrissi “Bovine TB” in The Art & Science of Tuberculosis 
Vaccine Development, 2nd Edition, 2014 http://tbvaccines.usm.my/finlay): 
• an efficient cattle identification system that allows effective tracing back to the herds of origin of 
tuberculous animals detected through slaughterhouse surveillance; 
• a high standard of meat inspection practices enabling effective surveillance for tuberculous lesions in 
animals passing through slaughterhouses; 
• an animal health information system for recording relevant information including epidemiological 
investigations, and data analysis to monitor progress and guide decision making; 
• a legal framework for enforcing control measures and compensating farmers for the slaughter of tuberculin 
positive reactors; 
• full control of movements of cattle including cross-border transhumance; 
Bovine Tuberculosis | Monograph 15 






• political support with cooperation of stakeholder groups involved and public awareness to ensure the 
success of the bovine TB control and eradication program; 
• public awareness campaigns and sensitization of farmers and the general public on bovine TB hazards and 
hygiene practices, and awareness of the objective, benefits, challenges and other implications of 
surveillance and control; 
• incentives for farmers to adhere to the eradication program, such as guaranteed milk prices and setting 
subsidies for disease free herds; 
• laboratory diagnostic capability for TB diagnosis based on the isolation and species identification of the 
bacterium from tuberculous lesions on organs, and, 
• financial resources, for adequate and speedy compensation of farmers for losses due to the removal of 
infected animals. 
These requirements are complex, expensive, and difficult to implement for most African countries.  The general 
lack of public resources in developing countries, seriously hampers such control strategies.  Also, many control 
measures will conflict with the customs and habits of the affected communities, so it is essential that the 
appropriateness of each possible intervention is assessed. The culling of sick animals might be seen as a loss of 
prestige, for example, while the keeping of livestock outdoors during the night might expose it to too great a risk 
of theft, and boiling will change the production and flavor of naturally soured milk. When possible, the negative 
effects of control strategies should be mitigated. The introduction of new probiotic organisms for milk souring 
may, for example, enable the fermentation of milk to continue as an acceptable practice, while limiting 
mycobacterial growth and infection [24]. 
 
Control of tuberculosis in wildlife 
This can be a major component of a control program and a big challenge, in places where wildlife is acting as 
maintenance host, like badgers in the UK, possums in New Zealand, or wild boar in Spain.  Culling to reduce the 
population density can decrease transmission, but it might not be a very popular measure and may have 
unanticipated effects, such as increasing the dispersal of the remaining members. Barriers can be used around 
certain areas to prevent wildlife access. Several control measures are being evaluated, for example vaccination 
of badgers in the UK, or oral baits with BCG vaccine in wild boar in Spain.  
Other measures:  
The high prevalence of bTB in African buffalo (Syncerus caffer) in regions of southern African has a negative 
economic impact on the trade of animals and animal products, represents an ecological threat to biodiversity, 
and poses a health risk to local communities through the wildlife-cattle-human interface. Test and cull methods 
may not be logistically feasible in many free-range wildlife systems, and with the presence of co-existing bTB 
hosts and the limited effectiveness of the BCG vaccine in buffalo, there is a need for alternative methods of bTB 
management. Selective breeding for increased resistance to BTB in buffalo may be a viable method of bTB 
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management in the future, particularly if genetic information can be incorporated into these schemes. This has 
been recently explored by Ie Roex et al, 2015: http://www.ncbi.nlm.nih.gov/pubmed/25985909. 
 
Disease situation and government policies by country 
Tables 8 and 9 below have been completed with the information received from the questionnaires sent to the 
DG and DVS.  For a list of respondents, please see Annex 2.   
Table 8 covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or control 
programs, and the treatment situation.  Table 9 refers to vaccination. 
 
The definitions that were given to the respondents are: 
1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely dissemination 
of information to those who need to know so that action can be taken.  
2Control: a program which is approved, and managed or supervised by the Veterinary Authority of a country for 
the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that country, 
or within a zone or compartment of that country. 
Table 8: Official status, official programs and treatment for bovine TB in the countries of interest.  
Information provided by the questionnaire sent to the DG/DVS as part of this monograph.  No responses 






















Bangladesh Yes Yes (targeted)* No N/A N/A 
Myanmar (Burma) Yes Yes, passive No No No 
Nepal Yes Yes, passive No No No 
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* Not clear if the respondent meant active, or referred to a certain area.  
**It is interesting to note, that Vietnam respondent said that treatment was authorized, and used frequently, as well that 
it was not a notifiable disease.  
Vietnam** No Yes, passive No Yes Yes 
AFRICA 
Côte d'Ivoire (Ivory 
Coast) 
Yes Yes, passive but 
active if outbreaks 
Yes - - 
Kenya Yes Yes, passive 
(abattoir) 
No No No 
Malawi Yes Yes, passive and 
active 
Yes N/A N/A 
Mali N/A Yes, passive  No No 
Rwanda  Yes Yes, passive and 
active 
No Yes No 
Tanzania  Yes Yes, passive and 
active 
No No No 
Uganda No No No No No 
Zambia Yes Yes, passive No N/A N/A 
 
Table 9: Vaccination for bovine TB in the countries of interest. Information provided by the questionnaire 
sent to the DG/DVS as part of this monograph. No responses were received from India, Indonesia, Burkina 











Who delivers the 
vaccine (official, 
private vaccinators or 
both) 
Species vaccinated (cattle, 
sheep, goats, pigs, poultry) 
ASIA 
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Bangladesh No N/A N/A N/A 
Myanmar (Burma) No - - - 
Nepal No N/A N/A N/A 
Vietnam* No Famers Private vaccinators Cattle 
AFRICA 
Côte d'Ivoire (Ivory 
Coast)  
No - - - 
Kenya No N/A N/A N/A 
Madagascar     
Malawi No N/A N/A N/A 
Mali No N/A N/A N/A 
Rwanda** No, but 
tuberculin test 
Government Official Cattle 
Tanzania  No N/A N/A N/A 
Uganda No N/A N/A N/A 
Zambia No N/A N/A N/A 
 
 *Again, it is interesting to note the response from Vietnam.  It Is surprising and raises concerns as to whether there may 
have been a misinterpretation or language barrier. 
** The reply refers to the tuberculin skin test, but it was left to reflect the country response.  
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BCG vaccine in livestock 
Currently, a commercial vaccine licensed for use in cattle for bTB does not exist. The vaccine for human TB, the 
BCG (a live attenuated M. bovis strain), has been used in cattle, and remains the best candidate vaccine for use 
in the field in the short to medium term [25]. Some advantages include that the vaccine is safe, relatively 
inexpensive, and is commercially produced for human application. The safety of BCG has been demonstrated for 
multiple host species, including cattle (strains Danish, Pasteur, Russia, Glaxo, Goteborg) in numerous trials over 
the past 90 years. The major caveats which have restricted its use, is that BCG protection is not complete. It 
limits mycobacterial burden and associated pathology in cattle but does not prevent infection. It also sensitises 
animals to respond in traditional TB tests. Potentially, these issues can now be overcome by using vaccination as 
part of a control program integrated with other control measures and using DIVA diagnostics [26]. 
History 
Waters et al, published in 2012 a good historical review [19] on the development of bTB vaccines (summarised 
here). Calmette and Guerin, developed an attenuated M. bovis vaccine (bacillus of Calmette and Guerin, BCG) by 
serial propagation of the bacillus on ox bile glycerine potato medium as a vaccine for M. tuberculosis infection of 
humans. Ironically, BCG was first evaluated and proven effective in cattle circa 1911, ten years prior to delivery 
of the vaccine to a human infant in 1921. 
During the 1920s, von Behring and others in Great Britain, France, Netherlands, Italy, Argentina, United States, 
and Japan tried immunization of cattle with different approaches and candidates, but besides BCG, none of 
these efforts proved both effective and practical. In the 1940s M. microti was also evaluated with reasonable 
results, but its use was not recommended due to variations in virulence of M. microti in cattle and interference 
with tuberculin skin tests. 
Numerous experimental and field trials were performed in the early to mid 1900s examining the use of BCG in 
cattle. While variations in study design as well as strains, doses, and routes of both BCG and virulent M. bovis 
challenge complicate comparisons between studies, some conclusions of these early studies are still applicable 
today. They include:   
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• a single dose of BCG provides non-sterile immunity to subsequent experimental challenge with virulent M. 
bovis 2–4 months after vaccination 
• field vaccination results in variable efficacy (0–80%)  
• live bacilli are required for protection  
Efficacy results for field trials with BCG performed between 1920 and 1982 ranged from complete to minimal 
benefit to no benefit. In 1953, an extensive field trial in England demonstrated inconclusive results with the use 
of BCG to protect cattle; therefore, use of the vaccine was not advised. Field trials with BCG performed during 
the mid 20th century failed to demonstrate a suitable level of protection. Potential reasons for failure were: 
generally high doses of BCG (108–1010 cfu parenterally) were used for vaccination, now known to be less 
effective than lower doses of BCG (103 to 106 Cfu parenterally); studies were often performed in regions with 
very high prevalence of M. bovis; and, calves may have been exposed to M. bovis very early in life prior to 
vaccination through consumption of milk from cows with tuberculous mastitis.  
More recent studies with BCG in cattle have confirmed prior favorable studies demonstrating reductions in 
disease severity (i.e., decreased M. bovis colonization and associated pathological changes) and considerable 
level of protection consistently in excess of 50%.  Additional conclusions of recent research include:  
• BCG is at least effective, and most likely, more effective when administered to neonatal calves compared to 
vaccination of older calves,  
• short interval BCG booster vaccination of young calves does not enhance protection,  
• the vaccine may be delivered orally with effective results provided adequate doses are given (see more 
information on doses below).  
 
Current status and challenges 
A very good summary has been recently published by Parlane and Buddle [26] and is the basis for this section. 
Over the past two decades, a large amount of knowledge has been acquired on the use of BCG through the 
harmonisation of cattle challenge models, BCG strains, and doses, and there have been an important number of 
recent developments (Table 10). Against experimental challenge with M. bovis, vaccination with BCG via 
subcutaneous or oral routes has repeatedly resulted in reductions in pathological and microbiological findings, 
although sterilising immunity is not produced. However, the experimental challenge is more severe than that 
observed following natural exposure as it is aimed to produce pathology in the majority of the non-vaccinated 
animals, while mimicking the pathology observed in naturally-infected cattle. 
BCG vaccine has been shown to be effective when administered at relatively low doses (103 to 106 CFU) 
subcutaneously or at higher doses (108 CFU) via the oral route, and by different daughter BCG strains (Pasteur 
and Danish). The OIE Terrestrial Manual says that a typical dose would be from 104 to 106 colony-forming units 
given SC, and the vaccine should be based on the standard reference strain, BCG Pasteur or Danish. Vaccination 
of neonatal calves (<1 month of age) induced higher levels of protection than those vaccinated at 6 months of 
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age [27][28]. This may be explained by the high numbers of circulating NK and γδ T cells in young calves which may 
lead to a robust innate response following vaccination and administration of BCG prior to presensitisation with 
environmental mycobacteria.  
One contentious attribute of BCG in cattle is the duration of immunity. A recent study using a stringent 
challenge model, demonstrated that BCG immunity may not be of long duration, with protection induced in 
calves vaccinated at 1 month of age and challenged 12 months later, while no significant protection was 
observed in another cohort challenged after 24 months [29].  Calves vaccinated as neonates and then 
revaccinated 6 weeks later had significantly reduced protection compared to those vaccinated once as neonates 
[27]. A recent study has demonstrated that BCG revaccination of cattle at 2 years after initial vaccination when 
immunity had waned boosted protection against challenge with M. bovis. In contrast, revaccination with either 
of two TB protein vaccines failed to enhance protection [30]. This study provided encouragement that protection 
could be produced in cattle following revaccination with BCG at 2 years after initial vaccination, and further 
studies are now required to optimise the timing of revaccination to provide long-term protection and to 
evaluate revaccination in the field situation. 
Field trials in Mexico, Ethiopia, and New Zealand have provided evidence for BCG to protect against natural 
exposure to M. bovis. In Mexico results showed a 59.4% efficacy [31] and in Ethiopia 56-68% protective efficacy 
[32]. The trial in Ethiopia also indicated that protection could last at least 22 months. A BCG field trial has just 
been completed on an isolated farm in New Zealand where M. bovis infection was endemic in wildlife (possums, 
ferrets, wild pigs, and wild deer). Over a 3-year period, five cohorts of cattle (ranging from 6 to 30 months of 
age) were tuberculin skin tested and reactor animals excluded from the study, but retained in the herd. Just over 
half of the almost 1,300 test-negative cattle were vaccinated orally with BCG mixed in a lipid matrix (Liporale, 
University of Otago, New Zealand), and the remainder left unvaccinated. These cattle were subsequently 
slaughtered at a commercial slaughterhouse when they reached their target weight for beef animals at 3 – 4 
years of age. An oral (rather than injected) preparation of BCG was used as it was considered likely to produce 
fewer BCG-induced positive skin test responses in tests conducted a year or more after vaccination. At the 
slaughterhouse, the animals were examined for tuberculous lesions and samples collected for bacterial culture. 
Of >1,200 animals inspected, preliminary analysis indicated that a significantly smaller percentage (~4 %) of 
vaccinated animals were infected with M. bovis compared with ~10 % for the non-vaccinated animals. The 
efficacy of the vaccine appeared to be high in the first year after vaccination [26]. 
Table 10:  Recent highlights in the development of TB vaccines for cattle (Source: Parlane and Buddle, 2015) 
 
Year Development References 
1995 Low doses of parenteral BCG protected against bovine TB [33] 
1999-2001 Use of specific M. bovis antigens in whole blood IFN-γ test could differentiate BCG-
vaccinated from M. bovis-infected cattle 
[34][35] 
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An additional challenge associated with BCG vaccination is that it compromises the specificity of tuberculin PPD-
based diagnostic tests such as skin tests.  Up to 80% of BCG-vaccinated cattle reacted positively to tuberculin 
skin test 6 months post-vaccination. However, the skin test reactivity rate decreased rapidly to ∼10–20% by 9 
months post-vaccination. Therefore, the BCG use in cattle and other domestic animals will require the 
development of a diagnostic test that can be used alongside vaccination to differentiate vaccinated and infected 
cattle (DIVA test). Please see recent developments under Diagnostics in Section 2.  
The BCG cattle vaccine is banned in the EU because it interferes with the tuberculin skin test and there is 
currently no validated test to differentiate infected from vaccinated animals. For the same reasons it is banned 
in the USA and many other countries.  
(https://www.gov.uk/government/publications/2010-to-2015-government-policy-bovine-tuberculosis-
bovine-tb/2010-to-2015-government-policy-bovine-tuberculosis-bovine-tb).  
Characteristics of the current BCG vaccine are included in the TPP in Table 11.  
 
2003-2005 BCG vaccine induced a high efficacy in calves <1 month old. [27][28] 
2003-2005 Combinations of TB DNA or protein vaccine with BCG induced protection greater than 
with BCG alone. 
[36][37] 
2009 BCG prime with viral vector vaccine boost enhanced protection against bovine TB. [38] 
2009 Vaccine-induced central memory immune response was a useful correlate of protection [38][39] 
2010 DIVA skin test was developed for differentiation of BGC-vaccinated from M. bovis-
infected cattle. 
[9] 
2011 Demonstrated that maintenance of antigen-specific skin test response was not required 
for protection 
[8] 
2012 BCG-induced immunity waned between 12-24 months post-vaccination. [29] 
2012 BCG strain overexpressing Ag85B induced better protection than that induced by wild-
type BCG strain 
[40] 
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Research is being conducted to improve the BCG vaccine, and it has been demonstrated that subunit vaccines 
may boost immunity elicited by BCG in cattle (See Section 8). 
 
Wildlife vaccines 
The efficacy of BCG delivered orally has been demonstrated for brushtail possums (in field trials) as well as 
Eurasian badgers, wild boar, and white-tailed deer (each in experimental challenge studies). Vaccine delivery to 
wildlife reservoirs is oral, although a parenteral route is being deployed for badgers in England.  
The major advantages of use of BCG in wildlife include: (1) the long history of use and safety in humans; thus, 
there is minimal concern for accidental exposure to humans, (2) proven efficacy when delivered orally in 
multiple species, (3) low cost of production, (4) commercially available sources of the vaccine and, (5) 
demonstrated efficacy with a single dose. Other vaccines evaluated for use in wildlife species include heat-killed 
M. bovis for use in wild boar, heat-killed M. vaccae in combination with live BCG for use in brushtail possums, 
and novel attenuated M. bovis mutants for use in brushtail possums [19]. 
Vaccination of wildlife present several unique challenges, especially with delivery. In general, the most practical 
method of delivery is via oral baits. Difficult to control variables for oral delivery include: dose, coverage (that is, 
the number of animals receiving the vaccine), age of vaccination, prior exposure to Mycobacterium spp. 
including M. bovis, vaccine uptake by non-target species, vaccine viability in the environment, and a controlled 
mechanism for revaccination in subsequent years. With oral baits, bait attractant and consistency must be 
optimized for each target host.  
 
Main vaccine needs: 
There is a need for a vaccine that: 
1. Provides sterile immunity 
2. Has a longer duration of immunity 
3. Has DIVA capabilities 
 
Human vaccines 
The BCG vaccines have been in use since the 1920s and while these protect very young children from the more 
invasive forms of TB, adolescents and adults are variably protected and remain susceptible to pulmonary 
diseases caused by M. tuberculosis.  The efficacy of current BCG vaccines against pulmonary TB disease is highly 
variable and is approximately 50% on average worldwide, while the efficacy against meningeal and miliary TB in 
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infants is relatively higher at about 75% in average (WHO Informal Consultation on Standardization and 




Commercial vaccines  
There are no commercial manufacturers of bTB vaccines, or of BCG vaccines specifically for cattle.  Search of the 
databases from the Center for Food Security & Public Health (Iowa State University), and Vetvac did not yield 
any results. The BCG manufactured for humans, is the vaccine that has been used in cattle.   
The BCG vaccine is in fact a range of different strains, as it became apparent that the subculture Calmette and 
Guérin distributed to laboratories around the world in the 1920s were evolving in different ways. It is now 
produced from samples emanating from 7 sites around the world, each with subtly different molecular and 
genetic characteristics. Different strains are named after these sites: BCG (Paris), BCG (Copenhagen) etc... This 
may result in different product characteristics. 
The BCG strain used most frequently since the mid-1980s was BCG Pasteur. However, mainly due to licensing 
issues, recently, the BCG strain of choice has become a freeze-dried preparation of BCG Danish produced by the 
Staten Serum Institute (Denmark). Equal protective efficacies of these two strains has been confirmed. 
 
Currently the WHO has a list of 5 pre-qualified BCG manufacturers (accessed 18 January 2016): 
 http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/ : 
1. BB-NCIPD Ltd.  Country of manufacture: Bulgaria.  Distributor: Intervax (Canada). 
2. Green Signal Bio Pharma Pvt. Ltd. Country of Manufacture: India 
http://www.gsbpl.com/index.php/products/bcg-vaccine  
3. Japan BCG Laboratory. Country of Manufacture:  Japan http://www.bcg.gr.jp/english/menu1.html  
4. Serum Institute of India Ltd, India. Country of Manufacture: India  
http://www.seruminstitute.com/content/products/product_bcg1.htm  
5. Statens Serum Institut. Country of Manufacture: Denmark. 
http://www.ssi.dk/English/Vaccines/BCG%20Vaccine%20Danish%20Strain%201331.aspx 
None of their websites mentions the vaccine being licenced in cattle.  
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The BCG strain used in the badger and cattle in the UK, is BCG Danish strain 1331 produced by the Statens Serum 
Institut in Copenhagen, Denmark, which is the strain licensed for human vaccination in the UK 
(http://veterinaryrecord.bmj.com/content/175/4/90.full.pdf+html).  The injectable badger vaccine is called 
BadgerBCG and has been available on prescription in the UK since March 2010. It is the same vaccine that the 
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The Target Product Profiles (TPPs) reflect the availability and utility of current agents and incorporate features 
that will be necessary to improve on the current products and to address unmet needs, taking into account the 
particular requirements of the poorest livestock keepers.   
The TPPs are more robust when they include the opinions and consider the needs of the different stakeholders.  
While efforts have been made to encompass them, the TPP showed in Table 11 below, should be considered a 
proposal, a live document subject to improvements.  
Information on current vaccines has been based on the BCG vaccine produced by SSI Denmark:  
http://www.ssi.dk/English/Vaccines/BCG%20Vaccine%20Danish%20Strain%201331/Discription%20of%20BCG
%20Vaccine%20SSI.aspx 
Table 11:  Target Product Profile (TPP) bovine TB – Proposal: 
 
 Attribute Minimum (current available vaccine) Ideal 
1 Antigen Live attenuated M. bovis  Immunogen with protective antigens for 
M. bovis and M. caprae (and M. 
tuberculosis?). 
2 Indication for use Theoretically (no licensed product): 
Reduction of disease severity and 
transmission in cattle (M. bovis) and 
goats (M. caprae) 
For active immunization of cattle, water 
buffalo, sheep, goats, pigs, camels and 
wildlife to prevent infection and 
transmission 
3 Recommended species Humans (currently there is no product 
licensed in animals)  
Cattle, buffalo, sheep, goats and pigs. 
Also all susceptible animals, including 
susceptible wildlife. 
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4 Recommended dose Cattle: 103 to 106 CFU SC, or at higher 
doses (108 CFU) via the oral route 
(High doses are known to be less 
effective) 
Same dose for all species (1 or 2 ml) 
5 Pharmaceutical form Freeze dried (powder and solvent for 
suspension) 
Ready to use solution/suspension 
6 Route of administration SC  
Has been used oral in wildlife and 
experimentally in calves 
SC or oral (oral route very important for 
wildlife) 
7 Regimen - primary 
vaccination 
One injection Single lifetime dose 
8 Regimen - booster When immunity wanes. Probably 
between 1 and 2 years.  
Lifelong immunity after primary 
vaccination 
9 Epidemiological relevance Protection against disease caused by 
M. bovis and M. caprae  
Protection against infection M. bovis 
and M. caprae   
10 Recommended age at first 
vaccination 
From one month of age (more 
effective in younger than older calves) 
From 1-2 months of age, when other 
vaccines are applied.  
11 Onset of immunity As soon as 25 days after vaccination <7 days  
12 Duration of immunity 1 year. No protection after 2 years.  Lifelong immunity 
13 Expected efficacy Reduction of disease severity and 
>50% protection. Does not prevent 
infection.  
To prevent infection and transmission in 
100% of the animals. No disease after 
virulent challenge. 
14 Expected safety 
 
No post-vaccinal reactions at any age. 
Safe for pregnant animals at any stage.  
Safe for all sexes at any age.  
15 Withdrawal period Nil Nil for milk and meat 
16 Special requirements for 
animals 
  Vaccinate all animals 
Bovine Tuberculosis | Monograph 15 







17 Special requirements for 
persons 
BCG is the human vaccine used at 
higher doses. People accidentally 
vaccinated will react to the vaccine. 
None 
18 Package size 1-5-10 vials. Each vial has 10 adult 
human doses (20 child doses) 
Multiple pack size from 5 doses 
19 Price to end user 
  
20 Storage condition and 
shelf-life as packaged for 
sale 
2℃-8℃ - 18 months Stable at 30°C for 24 months 
21 In-use stability  4 hours 24 hours or greater 
22 Other:  Interference with 
antibiotics 
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Scientific quality: The publications and data from the different research groups, should be carefully evaluated.  
The use of good science and good experimental design with use of proper controls, adequate numbers, suitable 
challenge model, reproduction of results by them and by independent groups, and appropriate analysis has not 
been verified for this monograph.  If any of these projects were to be pursued, a detailed peer review taking into 
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ANNEX 1:  Additional data on disease presence 
and incidence 
 
Reports to OIE on bovine TB: 
 
When different animal health statuses between domestic and wild animal population are provided, the box is 
split in two: the upper part for domestic animals, and the lower part for wild animals.  
Bovine TB in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam 
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Bovine TB in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal 
 
Bovine TB in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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Bovine TB in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
 
 
 
